IDYAIDEAYA Biosciences, Inc.

1. Aug 4, 2026IDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update.Earnings release · press release
2. Jun 23, 2026Effective June 16, 2026, the Company’s Board of Directors (the “Board”) elected Yujiro S. Hata as Chairman of the Board and Terry Rosen, Ph.D., as the Board’s Lead Independent Director.Shareholder vote results · Form 8-K
3. Jun 10, 2026Underwriting Agreement On June 8, 2026, IDEAYA Biosciences, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC, Jefferies LLC, TD Securities (USA) LLC, UBS Securities LLC and Cantor Fitzgerald & Co., as representatives (the “Representatives”) of …Other event · Form 8-K
4. Jun 3, 2026Clinical Collaboration with Roche in MTAP-Deleted RAS-Mutant Pancreatic Cancer On June 3, 2026, IDEAYA Biosciences, Inc. (the “Company”) announced it has entered into a clinical collaboration with F. Hoffmann-La Roche Ltd (“Roche”) to evaluate the efficacy and safety of IDE892, its investigational, potential …Other event · Form 8-K
5. Jun 1, 2026IDEAYA Biosciences and Servier Provide Complete Data from Phase 2/3 Registrational OptimUM-02 Trial of the Darovasertib Combination in First Line HLA*A2:01 Negative Metastatic Uveal Melanoma in a Late-Breaking Oral Presentation at ASCO On June 1, 2026, the Company and Les Laboratoires Servier (“Servier”) presented …Regulation FD disclosure · Form 8-K
6. May 5, 2026On May 5, 2026, IDEAYA Biosciences, Inc. (the “Company”) filed with the Securities and Exchange Commission (the “SEC”) an automatic shelf registration statement on Form S-3ASR (Registration No. 333-295560) (the “New Registration Statement”) to replace its existing automatic shelf registration statement on Form S-3 …Other event · Form 8-K
7. May 5, 2026IDEAYA Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update.Earnings release · press release
8. Apr 13, 2026Clinical Update On April 13, 2026, IDEAYA Biosciences, Inc. (the “Company”) and Servier, an independent international pharmaceutical group governed by a foundation, announced clinical data from the Company’s Phase 2/3 registrational trial, OptimUM-02, evaluating darovasertib in combination with crizotinib …Other event · Form 8-K
9. Apr 9, 2026On April 8, 2026, IDEAYA Biosciences, Inc. (the “Company”) entered into a clinical collaboration agreement with AstraZeneca plc (“AstraZeneca”) to evaluate the efficacy and safety of IDE849, the Company’s investigational, potential first-in-class DLL3 TOP1 antibody-drug conjugate, in combination with AstraZeneca’s …Other event · Form 8-K
10. Feb 17, 2026IDEAYA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update.Earnings release · press release
11. Jan 12, 2026On January 11, 2026, IDEAYA Biosciences, Inc. (the “Company”) provided a business update including an overview of key corporate objectives for 2026.Other event · Form 8-K
12. Jan 12, 2026Improving Lives Through Transformative.Regulation FD disclosure · press release

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.